The serum level of the amino‐terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone
- 1 March 2001
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 87 (4) , 348-351
- https://doi.org/10.1046/j.1464-410x.2001.00105.x
Abstract
Objective To assess the level of a bone-formation marker, the amino-terminal propeptide of type I procollagen (PINP), for its utility in indicating bone metastasis in patients with prostate cancer. Patients and methods Several bone formation markers, i.e. PINP, the carboxy-terminal propeptide of type I procollagen (PICP), bone-specific alkaline phosphatase (BALP), and bone Gla protein (BGP), a bone resorption marker (pyridinoline cross-linked carboxy-terminal telopeptide, ICTP), and prostate specific antigen (PSA) were measured in 40 patients without and 25 patients with bone metastasis. No patient had undergone previous treatment, except for six who developed bone metastasis while undergoing hormone therapy. Results All markers except BGP were significantly higher in patients with bone metastasis than in those without. The levels of PINP correlated best with the extent of disease, although the levels of PSA, BALP and ICTP also correlated well. While PINP had the largest area under the receiver-operator characteristic curve, PSA, BALP and ICTP also produced useful curves. Conclusion The bone formation marker PINP seems to be useful for discriminating patients with and without bone metastasis. PINP may help in the early and accurate diagnosis of bone metastasis in such patients.Keywords
This publication has 13 references indexed in Scilit:
- Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinomaScandinavian Journal of Clinical and Laboratory Investigation, 1999
- Dissociation of bone formation markers in bone metastasis of prostate cancerBritish Journal of Cancer, 1997
- Correlation Between Bone Metabolic Markers and Bone Scan in Prostatic CancerJournal of Urology, 1997
- Bone metabolic markers in bone metastasesZeitschrift für Krebsforschung und Klinische Onkologie, 1995
- Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancerBritish Journal of Cancer, 1995
- In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivoJournal of Bone and Mineral Research, 1994
- The Use of Prostate-Specific Antigen in Staging Patients With Newly Diagnosed Prostate CancerJAMA, 1993
- Biochemical Markers of Bone MetabolismAnnals of Medicine, 1993
- The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology, 1982